Gracell Biotechnologies developes FasT CAR-T, a breakthrough technology for hematological malignancies
Gracell Biotechnologies, a China-based immune cell gene therapy company has developed a faster and cheaper way of manufacturing CAR-T treatments.
FasT CAR-T, a revolutionary platform shortens the manufacturing time of CAR-T treatments from two weeks to one day.
FasT CAR-T also lowers manufacturing costs to a fraction of previous CAR-T therapies, while showing higher potency of CD19-directed FasT CAR-T ("CD19-F-CAR-T") in B-Cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin Lymphoma (NHL), both in vitro and in vivo.
With a first-in-human clinical study of CD19-F-CAR-T ongoing, Gracell said early clinical results show the therapy is safe and significantly more potent (20-40 times) than conventionally manufactured CAR-T agents (C-CAR-T) for treating B-ALL.
FasT CAR-T requires only one day for manufacturing (not including seven days for releasing tests per regulatory requirement), while C-CAR-T manufacturing takes about two weeks and another seven days for testing. Hence, FasT CAR-T reduces vein-to-vein time by an average of 12 days, which is critical for patients with rapidly progressing disease.
Source : Gracell Biotechnologies
Click here for the complete issue.